Most Read Articles
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
12 Aug 2019
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.

Metreleptin beneficial to patients with partial lipodystrophy

12 Jul 2019

Use of metreleptin for the treatment of patients with partial lipodystrophy (PL) is relatively safe and produces improvements in glycaemic control, hypertriglyceridaemia and liver volume, according to the results of an open-label study and its long-term extension phase.

The current analysis included 41 PL patients (median age, 34 years; 97.6 percent female) circulating leptin <12.0 ng/mL, and diabetes mellitus, insulin resistance or hypertriglyceridaemia who received metreleptin doses (once or twice daily) titrated to a mean of 0.124 mg/kg/day.

Treatment yielded significant reductions from baseline to month 12 in the following endpoints of interest: glycated haemoglobin (HbA1c; –0.6 percent) and fasting serum triglycerides (TGs; –20.8 percent), fasting plasma glucose (FPG; –1.2 mmol/L) and liver volume (–13.4 percent; p<0.05 for all).

The observed benefits extended to the subgroup of patients with baseline HbA1c ≥6.5 percent or TGs ≥5.65 mmol/L: HbA1c (−0.9 percent), fasting TGs (−37.4 percent), FPG (−1.9 mmol/L) and liver volume (−12.4 percent; p<0.05 for all). In this subgroup, 67.9 percent of patients achieved a ≥1-percent decrease in HbA1c or ≥30-percent decrease in fasting TGs, while 42.9 percent of patients achieved ≥2-percent or ≥40-percent reduction, respectively.

Long-term treatment with metreleptin in the said subgroup likewise resulted in substantial improvements in HbA1c, fasting TGs and FPG at months 12, 24 and 36 (p<0.05).

In terms of safety, the drug was well tolerated with no new safety signals. Commonly reported treatment-emergent adverse events were abdominal pain, hypoglycaemia and nausea.

The present data demonstrate the usefulness of metreleptin in the treatment of PL, especially for patients with more severe metabolic disease, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
12 Aug 2019
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.